Table 2.
miRNA profiles associated with specific molecular or cytogenetic abnormalities in acute myeloid leukemia and their targets.
| Disease and Specific Molecular Abnormalities | Dysregulated miRNAs | Predicted Target | Reference |
|---|---|---|---|
| CBF [t(8;21) and inv(16)] | miR-126/miR-126* (upregulated) | PLK2, SPRED1 | Li et al, 2008 |
| miR-193 (downregulated) | AMl1/ETO, DNMT3a, HDAC, KIT, CCND1, MDM2 | Li et al, 2013 | |
| miR221/222 (downregulated) | KIT | Brioschi et al, 2010 | |
| miR-9 (downregulated) | LIN28B/HMGA2 | Emmrich et al, 2014 | |
| miR-223 (downregulated) | Fazi et al, 2007 | ||
| t(15;17) | miR-224, miR-368, miR-382 (upregulated) | Notevaluated | Li et al, 2008 |
| miR-181 (downregulated) | Notevaluated | Nowak et al, 2012 | |
| Disease and Specific Molecular Abnormalities | Dysregulated miRNAs | Predicted Target | Reference |
|
miR-15a, miR-15b, miR-16, miR-142, miR-181b, miR-223, let-7a, let-7d (upregulated); miR-107, miR-342, let-7c (downregulated) |
Not evaluated | Careccia et al, 2009 | |
| MLL-rearrangements | miR-17-5p, miR17-3p, miR-18a, miR-19a, miR-20a, miR-19b, miR-92 (polycistronic) (upregulated) | not evaluated | Li et al, 2008 |
|
miR-191 (upregulated) miR-29 (downregulated) |
not evaluated | Garzon et al, 2008 | |
| NPMc+ | miR-10a, miR-10b, let-7, miR-29 family, miR-15a-16-1, miR-17-18a-19a-20a cluster(upregulated) | HOXAB4 (miR-10); HAXA10 MEIS1 (miR-204) | Garzon et al, 2008 |
| FLT3-ITD | miR-155 (upregulated) | Garzon et al, 2008 | |
| miR-181 family, miR-124, miR-128, miR 194, miR-219, miR-220a, miR-320(upregulated) | Toll-like receptors, IL1-beta, CARD (caspase recruitment domain) | Marcucci et al, 2008 | |
| RUNX1mutated |
let-7, miR-223, miR-99a, miR-100 (downregulated) miR-211, miR-220, miR-595(upregulated) |
Not evaluated | Mendler et al, 2012 |
| BAALCoverexpressed | miR-3151(upregulated) | TP53 pathway | Eisfeld et al, 2014 |
Annotations: CBF, core binding factor; MLL, myeloid and lymphoid gene; NPMc+, nucleophosmin cytoplasmic positive; FLT3-ITD, fms-like tyrosine receptor internal tandem duplications; BAALC, brain and acute leukemia cytoplasmic.